News

24/7 Wall St. on MSN10h
Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Houston Public Media2d
Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...
News 91d
Discounts available for weight loss drugs not covered by insurance
In this edition of Daily Dose, Dr. Lacy Anderson answers a viewer's question about what discounts are available for weight ...
FDA stops sale of generic versions of Ozempic and Wegovy: What to do if you’re taking them
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
Obesity drug boom has a new pecking order
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
North Penn Now4d
Alternatives to Compounded Semaglutide & Tirzepatide: Affordable & Effective Options for Patients In The USA
"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...